Eiger Biopharmaceuticals Inc (EIGR) Key Ratios
$2.27
As on 10-May-2024 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$16 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 18.51 | 41.06 | 16.98 | 40.04 | -- |
| EBIT | 29.78 | 50.86 | 23.70 | -5.33 | -10.11 |
| Net Profit | 25.38 | 46.48 | 23.13 | -5.36 | -10.66 |
| EPS | 25.35 | 46.77 | -168.91 | -368.59 | -262.77 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-23 | Dec-22 | Dec-21 |
| EBIT-Margin
| -587.34 | -711.04 | -440.57 | -687.78 | -633.66 |
| Net Margin
| -384.56 | -1,353.52 | -- | -711.43 | -57.69 |
| Return on equity
| -186.36 | -153.87 | -367.00 | -151.56 | -40.51 |
| Return on Capital
| -82.79 | -78.65 | -122.63 | -96.56 | -29.18 |
| Return on Assets
| -65.98 | -64.82 | -94.31 | -78.51 | -25.12 |
| Debt to Equity (x)
| -- | -- | -2.85 | 0.73 | 0.45 |
Profitability
ROCE
-122.63
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-122.63
|
-96.56
|
-29.18
|
-63.47
|
-81.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-367.00
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-367.00
|
-151.56
|
-40.51
|
-90.60
|
-119.67
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-94.31
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-94.31
|
-78.51
|
-25.12
|
-55.19
|
-70.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-440.57
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-440.57
|
-687.78
|
-633.66
|
-1,082.17
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-475.26
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-475.26
|
-711.43
|
-57.69
|
-1,066.56
|
-3,578.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
0.17
--
Year on year growth in net sales
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.17
|
0.11
|
1.11
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
25.07
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
25.07
|
-20.54
|
-23.80
|
9.80
|
-37.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
22.54
--
Year on year growth in profit after tax
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
22.54
|
-185.33
|
50.58
|
6.80
|
-40.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
0.23
--
Year on year growth in earnings per share
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.23
|
-65.06
|
0.57
|
0.24
|
-0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-2.85
--
Total debt / Net worth
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-2.85
|
0.73
|
0.45
|
0.34
|
0.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-2.85
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-2.85
|
0.01
|
0.12
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.71
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.71
|
4.68
|
3.46
|
8.29
|
5.92
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
0.68
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.68
|
4.57
|
3.37
|
8.28
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-12.71
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-12.71
|
-22.44
|
-21.62
|
-17.29
|
-20.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.66
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
10.66
|
12.97
|
21.22
|
133.34
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.20
--
Sales / Average Total Assets
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.20
|
0.11
|
0.09
|
0.05
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
39.73
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
39.73
|
58.58
|
153.93
|
487.04
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
33,549.73
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
33,549.73
|
543.30
|
663.09
|
52.66
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
84,387.97
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
84,387.97
|
1,664.20
|
3,040.89
|
3,129.82
|
4,600.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-50,798.51
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-50,798.51
|
-1,062.32
|
-2,223.87
|
-2,590.12
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.00
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
0.00
|
-0.02
|
-5.20
|
-5.35
|
-4.96
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
-0.02
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-0.02
|
0.03
|
2.44
|
3.86
|
6.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.23
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Eiger Biopharmaceuticals Inc (EIGR)
|
-0.23
|
0.62
|
-3.97
|
-4.45
|
-4.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|